Progress of apatinib in treatment of lung cancer / 肿瘤研究与临床

ABSTRACT

Lung cancer is the most common malignant tumor. As the first-generation oral small-molecule tyrosine kinase inhibitor independently developed in China, apatinib can block many kinds of signaling pathways with high selectivity, and play an anti-tumor effect by inhibiting tumor angiogenesis, and the adverse reactions are controllable. More and more studies have shown that apatinib can be used for the second-line and beyond treatment of patients with advanced non-small cell lung cancer. This article reviews the mechanisms and clinical studies of apatinib in treatment of lung cancer.